Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription 25.08.2025 1 Antimicrob Agents Chemother 3 Clin Infect Dis 1 Eur Respir J 1 Infect Immun 1 J Antimicrob Chemother 1 J Clin Microbiol 2 PLoS One 1 Respir Med

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Antimicrob Agents Chemother

1. ZHANG M, Allen R, Ames L, Engelhart CA, et al
   Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2025 Aug 19:e0036825. doi: 10.1128/aac.00368.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. LAW S, Fulcher I, Ashraf S, Bastard M, et al
   Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling.
   Clin Infect Dis. 2025 Aug 22:ciaf467. doi: 10.1093.
   PubMed         Abstract available
   
   
3. POORE H, Wambi P, Nkereuwem E, Nakafeero J, et al
   The three-gene Xpert Host Response signature for pediatric tuberculosis screening: A prospective diagnostic accuracy study.
   Clin Infect Dis. 2025 Aug 21:ciaf445. doi: 10.1093.
   PubMed         Abstract available
   
   
4. SINHA P, Bhargava M, Dauphinais MR, Carwile ME, et al
   In-kind Nutritional Supplementation for Persons With Drug-susceptible Tuberculosis and Their Household Contacts Would be Cost-effective for Reducing Tuberculosis Incidence and Mortality in Jharkhand, India: A Modeling Study.
   Clin Infect Dis. 2025 Aug 20:ciaf400. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Eur Respir J

5. LANGE C, Barry C 3rd, Sotgiu G
   Linezolid for the treatment of drug-resistant tuberculosis.
   Eur Respir J. 2025;66:2500927.
   PubMed        
   
   

   
   Infect Immun

6. LI J, Wang Y, He L, Yang L, et al
   Host-directed therapeutic targets in macrophages and their ligands against mycobacteria tuberculosis.
   Infect Immun. 2025 Aug 25:e0006325. doi: 10.1128/iai.00063.
   PubMed         Abstract available
   
   

   
   J Antimicrob Chemother

7. SAMUELSSON T, Lonnermark E, Sundell J, Yilmaz A, et al
   Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index.
   J Antimicrob Chemother. 2025 Aug 21:dkaf300. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Clin Microbiol

8. RISCH P, Broger T, Booi Z, Tiseo K, et al
   AveloMask, a novel breath aerosol collection kit for airborne Mycobacterium tuberculosis: a proof-of-principle assessment.
   J Clin Microbiol. 2025 Aug 21:e0054625. doi: 10.1128/jcm.00546.
   PubMed         Abstract available
   
   

   
   PLoS One

9. GALLEGATI M, Lopreite M, Puliga M
   Modeling the formation of a worldwide health network fighting TBC: Key drivers in policy, management and governance in developing countries and global health institutions.
   PLoS One. 2025;20:e0330538.
   PubMed         Abstract available
   
   
10. MAENETJE N, Oladimeji M, Mlotshwa M, Hoft D, et al
    Epidemiological factors associated with immunological resistance in household contacts exposed to active tuberculosis in South Africa: A logistic regression analysis.
    PLoS One. 2025;20:e0329562.
    PubMed         Abstract available
    
    

    
    Respir Med

11. AUTENTICO ART, Lim BA
    Characteristics and in-hospital outcomes of clinically diagnosed tuberculosis patients in a high-burden setting: A five-year retrospective analysis.
    Respir Med. 2025;247:108309.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.